Table 1.

Inclusion/Exclusion criteria for the phase I trial of autologous HSPPC-96 in the recurrent setting of glioblastoma [49].

Inclusion Criteria	Exclusion Criteria
Recurrent grade III or IV glioma KPS ≥ 60, life expectance > 8 weeks. ≥4 vaccines available for use	Treatment with corticosteroids at time of resection Hx of immunodeficiency, immunosuppressive drug use excluding corticosteroids, current malignancies at other sites or other cancers within 5 years Uncontrolled active infection